Ophthalmology

A group of investigators, researchers and policymakers discuss the issues, innovations and aspirations that may define 2023 advances.

From a topical gene therapy to a debated heart failure option, a litany of unique agents are anticipated for FDA decision in the new year.

A new Q&A focuses on hybrid telehealth in ophthalmology and subspecialty-level care, and its potential to create new opportunities and increase access for patients.

A moderate negative correlation was observed between changes in BCVA and changes in CST at weeks 12 and 24.

Patients with DR who received intravitreal anti-VEGF injections had a risk of cardiovascular events similar to those who received laser or steroid treatment

A retrospective cohort analysis of patients in Finland show a notable overlap of the 2 forms of vision loss.

An analysis of the change from preoperative to final BCVA showed no difference between the deferred and immediate surgery subgroups.

SB11 and ranibizumab appeared to have comparable immunogenicity and safety profiles in a post-hoc analysis of a phase 3 equivalence trial.

People with diabetes were 11% more likely to develop glaucoma and/or OHT, and individuals with glaucoma and/or OHT were 12% more likely to develop diabetic retinopathy.

After decades of unmet needs in the progressive form of vision loss, the complement inhibitor drug class is nearing the market for affected patients.

New research suggests lower central foveal thickness fluctuation scores with patients on ranibizumab were associated with the greatest gains in vision.

Dr. Glasser shares perspective on the adoption of telehealth in ophthalmology and the importance of increased funding to provide sufficient reimbursement for all physician services.

Individuals living in lower-income situations were also more likely to have vision impairment, use eye care services less, and have lower adherence to eye examinations.

Macular holes in stage 2 progress faster than those in stages 3 and 4, making it beneficial to perform vitrectomy without delay in this population.

The results from the artificial intelligence deep learning model indicated alterations in the SD-OCT imaging regions attributed to the retinal nerve fiber and choroid layers.

Adults with vision impairment had a lower prevalence of having health insurance coverage and a usual health care provider, and a higher prevalence of having an unmet health care due to cost.

A clinical trial from Norway showed inconclusive results, and challenges in the study design.

Visual complaints during atropine therapy may be reduced by using progressive addition lenses.

A recent quality improvement study demonstrated the potential to enhance ophthalmic telehealth using asynchronous testing, which was effective in subspecialty-level care.

The study reported 6.1% of study patients with NTG had ODD diagnosed using EDI-OCT, compared to the 1.8% – 2.0% reported in the general population.

The implant significantly reduced CRT in patients with RVO-ME, but the study reported no relationship between OCT biomarkers and clinical outcomes.

Myopia progressed slower in the highly aspherical lenslet spectacle subset compared to single vision spectacles during the first 2 stages of the study.

The findings may support the use of macular imaging for monitoring at the time of glaucoma diagnosis and for monitoring the rate of GCC thinning.

Neither the retinal disease nor the VEGF inhibitor type was significantly associated with rhegmatogenous retinal detachment risk.

The mean PCDP was estimated by 2 different methods to be 10.7 years and 10.1 years for open-angle glaucoma.

The post-hoc analysis suggests reliable quantification of photoreceptor loss is an essential tool to evaluate therapeutic efficacy in slowing GA progression.

Two-thirds of eyes achieved a good visual outcome of 20/40 or better after cataract surgery among individuals with T2D.

Difluprednate treatment after AGV implantation resulted in a similar IOP and fewer glaucoma medications compared with prednisolone acetate.

Greater glaucoma polygenic risk was associated with faster structural and functional progression in early POAG, despite individuals receiving more intensive treatment.

The analysis additionally suggested the potential benefits of finerenone in the prevention of required ocular interventions.